BR112018012343A2 - composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos - Google Patents

composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos

Info

Publication number
BR112018012343A2
BR112018012343A2 BR112018012343A BR112018012343A BR112018012343A2 BR 112018012343 A2 BR112018012343 A2 BR 112018012343A2 BR 112018012343 A BR112018012343 A BR 112018012343A BR 112018012343 A BR112018012343 A BR 112018012343A BR 112018012343 A2 BR112018012343 A2 BR 112018012343A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
neurodegenerative disorders
treating neurodegenerative
polyhydroxylated
Prior art date
Application number
BR112018012343A
Other languages
English (en)
Inventor
Patnaik Debasis
Tsai Li-Huei
Pao Ping-Chieh
J Haggarty Stephen
Original Assignee
Massachusetts Inst Technology
The General Hospital Corp D/B/A Massachusetts General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, The General Hospital Corp D/B/A Massachusetts General Hospital filed Critical Massachusetts Inst Technology
Publication of BR112018012343A2 publication Critical patent/BR112018012343A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/825—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/20—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/34—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção se refere a compostos de benzofenona poli-hidroxilada úteis no tratamento de doenças neurodegenerativas, neurológicas, psiquiátricas e cognitivas, em particular aquelas associadas a uma deficiência em atividade de hdac1 deacetilase.
BR112018012343A 2015-12-17 2016-12-19 composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos BR112018012343A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268899P 2015-12-17 2015-12-17
PCT/US2016/067592 WO2017106861A1 (en) 2015-12-17 2016-12-19 Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BR112018012343A2 true BR112018012343A2 (pt) 2018-12-04

Family

ID=59057697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012343A BR112018012343A2 (pt) 2015-12-17 2016-12-19 composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos

Country Status (13)

Country Link
US (2) US11180438B2 (pt)
EP (1) EP3390347A4 (pt)
JP (1) JP2019504827A (pt)
KR (1) KR20180101404A (pt)
CN (1) CN109071417A (pt)
AU (1) AU2016369642A1 (pt)
BR (1) BR112018012343A2 (pt)
CA (1) CA3008854A1 (pt)
CL (1) CL2018001633A1 (pt)
IL (1) IL260046A (pt)
MX (1) MX2018007458A (pt)
RU (1) RU2018126187A (pt)
WO (1) WO2017106861A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111393277B (zh) * 2020-03-15 2023-01-03 山西医科大学 4-丁基多羟基二苯甲酮类化合物衍生物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257272B1 (pt) * 1974-01-15 1978-08-25 Pharmascience Labo
JPH02206A (ja) * 1987-11-11 1990-01-05 Fujisawa Pharmaceut Co Ltd エキシホンと水溶性高分子化合物とを含有することを特徴とする新規製剤
ES2043766T3 (es) * 1987-11-11 1994-01-01 Pharmascience Lab Una nueva composicion farmaceutica que comprende exifona y un polimero soluble en agua.
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US6777578B2 (en) 2000-04-27 2004-08-17 Arizona Board Of Regents Hydroxyphenstatin and the prodrugs thereof
GB0724989D0 (en) * 2007-12-21 2008-01-30 Univ Sheffield Novel compounds
CN102159203A (zh) * 2008-07-23 2011-08-17 麻省理工学院 组蛋白脱乙酰酶1(hdac1)的活化防范dna损伤和增加神经元存活
JP6240063B2 (ja) * 2011-04-28 2017-11-29 ザ ブロード インスティテュート， インコーポレイテッド ヒストンデアセチラーゼ阻害剤
HUE042006T2 (hu) * 2011-07-22 2019-06-28 Massachusetts Inst Technology Hiszton-dezacetilázok (HDACS) I osztályának aktivátorai és ezek alkalmazása
WO2014127191A1 (en) * 2013-02-15 2014-08-21 The Regents Of The University Of Michigan Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins
ES2862126T3 (es) * 2013-10-10 2021-10-07 Acetylon Pharmaceuticals Inc Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa

Also Published As

Publication number Publication date
US20210171429A1 (en) 2021-06-10
US11180438B2 (en) 2021-11-23
EP3390347A1 (en) 2018-10-24
CL2018001633A1 (es) 2019-01-18
IL260046A (en) 2018-07-31
RU2018126187A (ru) 2020-01-20
WO2017106861A1 (en) 2017-06-22
EP3390347A4 (en) 2019-07-24
CN109071417A (zh) 2018-12-21
JP2019504827A (ja) 2019-02-21
AU2016369642A1 (en) 2018-08-02
MX2018007458A (es) 2018-11-29
US20200087236A9 (en) 2020-03-19
US11639325B2 (en) 2023-05-02
KR20180101404A (ko) 2018-09-12
US20180290960A1 (en) 2018-10-11
CA3008854A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
BR112018011709A2 (pt) inibidores bicíclicos de pad4
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
TN2017000134A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
SA517381713B1 (ar) تركيبة أطلاق معدلة من الأورليستات والأكارابوز لعلاج السمنة واضطرابات التمثيل الغذائي ذات الصلة
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
BR112017025263A2 (pt) método para o tratamento de doença neurológica
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
BR112018012343A2 (pt) composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos
ITUA20161679A1 (it) Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
PH12020500472A1 (en) Autotaxin inhibitor compounds
PH12016500824A1 (en) Compositions and methods for the treatment of viral diseases with pde4 modulators
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements